NKGN VS SYRS Stock Comparison
Performance
NKGN10/100
10/100
NKGN returned -53.87% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.
SYRS10/100
10/100
SYRS returned -32.17% in the last 12 months. Based on SPY's performance of -11.19%, its performance is below average giving it a score of 10 of 100.
Volatility
NKGN10/100
10/100
NKGN has had a lower than average amount of volatility over the last 12 months giving it a score of 10 of 100.
SYRS45/100
45/100
SYRS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
Analyst Price Targets
NKGN
"Analyst Price Targets" not found for NKGN
SYRS75/100
75/100
7 analysts offer 12-month price targets for SYRS. Together, they have an average target of 30, the most optimistic target put SYRS at 30 within 12-months and the most pessimistic has SYRS at 30.
Technicals
NKGN
"Technicals" not found for NKGN
SYRS36/100
36/100
SYRS receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.
Earnings
NKGN
"Earnings" not found for NKGN
SYRS10/100
10/100
SYRS has missed earnings 7 times in the last 20 quarters.
Profit
NKGN
"Profit" not found for NKGN
SYRS10/100
10/100
Out of the last 20 quarters, SYRS has had 0 profitable quarters and has increased their profits year over year on 1 of them.
All score calculations are broken down here to help you make more informed investing decisions
NKGen Biotech, Inc. Common Stock Summary
Nasdaq / NKGN
Healthcare
Biotechnology
Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.
Syros Pharmaceuticals, Inc. Common Stock Summary
Nasdaq / SYRS
Healthcare
Biotechnology
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare NKGN to other companies in the same or a similar industry.